2013-01-30 14:18:35 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Laboratorios Farmaceuticos ROVI SA and produced a Rating Update Report, rating the company's attractiveness to long-term investors.

Ilhavo, Portugal – SADIF Investment Analytics, announces a new Rating Update Report covering Laboratorios Farmaceuticos ROVI SA (ROVI). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Laboratorios Farmaceuticos ROVI SA investor.

Report Summary: Laboratorios Farmaceuticos ROVI SA is an above average quality company with a neutral outlook. Laboratorios Farmaceuticos ROVI SA has strong business growth and is run by efficient management. The trend in Laboratorios Farmaceuticos ROVI SA fair value exchange rate against its closest rated-competitor, Krka d.d. Novo Mesto, has been appreciating over the past 2 weeks. When compared to its closest competitor, Laboratorios Farmaceuticos ROVI SA shows similar overvaluation and is equally likely to outperform the market.

The 3-page report

breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Laboratorios Farmaceuticos ROVI SA for long-term investors.

The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
www.sadifanalytics.com/stockmarks/company-ru-470-ROVI

About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.